KR20120032009A - Agent for preventing or treating abnormality in skin water permeation function - Google Patents

Abstract

An object of the present invention is to provide a prophylactic or therapeutic agent for abnormal skin moisture permeation function that can improve the moisture content control effect of the skin by adjusting the TEWL according to the skin condition to make the skin water permeation function healthy.
Purine nucleic acid has an effect of appropriately adjusting TEWL according to the skin condition, and is used as an active ingredient of a prophylactic or therapeutic agent for abnormal skin moisture permeation function.

Description

{AGENT FOR PREVENTING OR TREATING ABNORMALITY IN SKIN WATER PERMEATION FUNCTION}

The present invention relates to a prophylactic or therapeutic agent for abnormal skin moisture permeation function. The present invention also relates to agents for controlling transepidermal water loss (TEWL), which indicates the amount of water evaporation from the skin, in a healthy range. The present invention also provides a method for preventing or treating skin moisture permeation dysfunction, a method for adjusting TEWL value, a method for preventing or treating abnormal TEWL in skin, a method for improving skin water permeation function; And uses thereof.

Skin plays several roles. The main role of the skin is to protect against ultraviolet rays, foreign substances, microorganisms, etc. Also, the outermost layer of the skin has a moisture content control function, contributing to skin homeostasis.

The skin typically has an appropriate range of elasticity, plasticity, or strength to cope with physical forces. However, this requires a flexible one, including an appropriate amount of moisture.

However, the skin is in a very dry state because it is located in the outermost layer. The outer skin layer contains a natural moisturizing factor (NMF) or ceramide, and by combining them, the entire skin can be maintained in a flexible skin state by retaining an appropriate amount of moisture.

When the amount of water evaporation from the skin becomes excessive, it is known that the skin becomes dry, which causes skin aging and wrinkles.

On the other hand, it is known that the skin surface becomes rough and dry also by thickening and deposition of the stratum corneum. This is because the stratum corneum thickens or accumulates due to a decrease in cellular function, thereby degrading skin moisture permeability. For this reason, in recent years, skin peeling by chemical peeling etc. is performed in order to improve the thickening and deposition of a stratum corneum. However, these are often more likely to peel off the skin than necessary to damage the skin.

In addition, the moisture permeability decreases with aging, and as a result, it is known to cause senile dry skin accompanied by itching, cracked skin, and the like.

However, for the above skin disorders, temporary symptomatic treatments such as coating the skin to maintain moisture have been widely used. In these therapies, the TEWL is reduced by inhibiting the skin water permeation function, which leads to the inhibition of the water amount control function, which is the original function of the skin. As such, techniques for maintaining moisture in the stratum corneum have been widely studied. However, conventionally, there has been no research on ingredients that exert the original function of the skin by improving the skin moisture control function by increasing or decreasing the skin moisture permeation function according to the symptoms.

In general, when the TEWL value rises, the water evaporation from the skin increases and the skin becomes dry. On the other hand, by maintaining the moisture to suppress the TEWL value and the moisture permeation through the skin to control the moisture evaporation from the skin. Human skin is sensitive to dryness, eczema, etc. Each skin area has different properties. However, it is difficult to selectively use agents effective on increasing or decreasing the TEWL value depending on the skin area. Therefore, there has long been a need for the development of a single formulation that can adjust the TEWL value to an appropriate range by increasing and decreasing the TEWL value depending on the skin area.

Against this background, there has been a long demand for the development of a component that can improve the moisture permeation function by adjusting the TEWL of the skin to an appropriate range.

Japanese Patent Laid-Open No. 2007-246459

An object of the present invention is to provide a prophylactic or therapeutic agent for abnormal skin moisture permeation function that can improve the moisture content control function of the skin by adjusting the TEWL according to the skin condition to a healthy state. It is also an object of the present invention to provide a TEWL value adjusting agent which properly hydrates water from the epidermis while maintaining the proper amount of water in the skin. Moreover, an object of this invention is to provide the preventive or therapeutic agent of abnormal TEWL of skin, or the skin moisture permeation function improving agent.

MEANS TO SOLVE THE PROBLEM The present inventors earnestly examined in order to solve the said subject. As a result, it was found that purine nucleic acid has an effect of appropriately adjusting the TEWL value according to the skin condition. Specifically, the inventors have found that purine nucleic acids can increase TEWL values to healthy ranges for TEWL-reduced skin and also reduce TEWL to healthy ranges for skin showing excess TEWL. ; Therefore, purine nucleic acid can prevent or treat abnormality of water permeation function of skin. As a result, the inventors have found that the regulation of TEWL values by purine nucleic acids prevents and improves abnormal skin conditions such as rough skin, itching, cracked skin; Furthermore, it was found to be effective against skin diseases such as hyperkeratosis and senile dry skin. The inventors have also found that purine nucleic acid has an effect of properly evaporating moisture from the epidermis while maintaining an appropriate amount of skin moisture. This invention is completed by further examining based on these knowledge.

More specifically, the present invention provides a prophylactic or therapeutic agent for abnormal skin moisture permeation function having the following characteristics.

Item 1-1. A prophylactic or therapeutic agent for abnormal skin moisture permeation function comprising at least one purine nucleic acid as an active ingredient.

Item 1-2. The agent for preventing or treating abnormality in skin moisture permeation function according to item 1-1, wherein at least one purine nucleic acid is selected from the group consisting of adenosine monophosphate and salts thereof.

Item 1-3. The prophylactic or therapeutic agent according to item 1-1, wherein the purine nucleic acid is contained in an amount of 0.1 to 20% by weight.

Item 1-4. A prophylactic or therapeutic agent for abnormal skin moisture permeation function according to item 1-1, which is used to adjust the TEWL (transdermal moisture evaporation amount) value.

Item 1-5. A prophylactic or therapeutic agent for abnormal skin moisture permeation function according to item 1-1, which is used for preventing or treating a skin condition or a skin disease having an abnormal TEWL value.

Item 1-6. The preventive or therapeutic agent for skin moisture permeation abnormality according to item 1-1, wherein the skin moisture permeation abnormality is due to aging.

Item 1-7. A prophylactic or therapeutic agent for abnormal skin moisture permeability according to item 1-1, which is used for preventing or treating rough skin, itching, cracked skin, hyperkeratosis, or senile dry skin.

Item 1-8. The preventive or therapeutic agent for abnormal skin moisture permeability according to item 1-1, which is a cosmetic, an external skin medicine or an external quasi drug.

Item 1-9. The prophylactic or therapeutic agent of the above-mentioned skin moisture permeation function of Claim 1-1 used for non-treatment.

Item 1-10. Use of at least one purine nucleic acid for preparing an external composition for preventing or treating skin moisture permeability.

Item 1-11. Use of at least one purine nucleic acid for the prevention or treatment of abnormal skin moisture permeation function in an external composition.

Item 1-12. Purine nucleic acids for preventing or treating skin water permeation dysfunction.

Item 1-13. A method of preventing or treating skin moisture permeation dysfunction comprising administering at least one purine nucleic acid to a subject in need thereof.

The present invention also provides an invention relating to a modulator of TEWL (hard epidermal moisture evaporation) value having the following characteristics.

Item 2-1. A modulator of TEWL (hard epidermal moisture evaporation amount) value containing at least one purine nucleic acid as an active ingredient.

Item 2-2. The modulator of TEWL value according to item 2-1, wherein at least one purine nucleic acid is selected from the group consisting of adenosine monophosphate and salts thereof.

Item 2-3. A modulator of TEWL value according to item 2-1, wherein the purine nucleic acid is contained in an amount of 0.1 to 20% by weight.

Item 2-4. The modulator of TEWL value according to item 2-1, used to improve skin moisture permeation function.

Item 2-5. A modulator of TEWL value according to item 2-1, which is used to prevent or treat a skin condition or skin disease having an abnormal TEWL value.

Item 2-6. A modulator of TEWL value according to item 2-1, used to prevent or treat rough skin, itching, cracked skin, hyperkeratosis, or senile dry skin.

Item 2-7. The modulator of TEWL value of the claim | item 2-1 which is cosmetics, an external skin medicine, or an external aquatic drug.

Item 2-8. A modulator of TEWL value according to item 2-1, used for non-treatment.

Item 2-9. Use of at least one purine nucleic acid for preparing an external composition for controlling TEWL (hard epidermal moisture evaporation) value.

Item 2-11. Use of at least one purine nucleic acid for controlling TEWL (hard epidermal moisture evaporation) value in an external composition.

Item 2-12. Purine nucleic acid for controlling TEWL (hard epidermal moisture evaporation) value.

Item 2-13. A method of controlling a TEWL (transdermal moisture transpiration) value comprising administering at least one purine nucleic acid to a subject in need thereof.

The present invention also provides the following agents, uses and methods of the compounds.

Item 3-1. A prophylactic or therapeutic agent for abnormal TEWL (hard epidermal water evaporation amount) of skin containing at least one purine nucleic acid as an active ingredient.

Item 3-2. Use of at least one purine nucleic acid for the preparation of an external composition for the prevention or treatment of abnormal TEWL (light epidermal water evaporation) of skin.

Item 3-3. Use of at least one purine nucleic acid for preventing or treating abnormal TEWL (hard epidermal water evaporation amount) of skin in an external composition.

Item 3-4. Purine nucleic acid for preventing or treating abnormal TEWL (light epidermal water evaporation) of skin.

Item 3-5. A method of preventing or treating abnormal TEWL (transepidermal hydration) of skin, comprising administering at least one purine nucleic acid to a subject in need of preventing or treating abnormal TEWL of skin.

Item 3-6. An agent for improving skin moisture permeation, comprising at least one purine nucleic acid as an active ingredient.

Item 3-7. Use of at least one purine nucleic acid for preparing an external composition for improving skin moisture permeation function.

Item 3-8. Use of at least one purine nucleic acid for improving skin water permeation function in an external composition.

Item 3-9. Purine nucleic acid for improving skin moisture permeation function.

Item 3-10. A method of improving skin moisture permeation function comprising administering at least one purine nucleic acid to a subject in need thereof.

According to the present invention, by adjusting the TEWL value according to the skin condition, the water permeation function of the skin can be maintained in a healthy state, thereby improving the water content control action of the skin. Further, according to the present invention, it becomes possible to prevent or treat skin conditions and skin diseases having abnormal skin moisture permeability, such as rough skin, itching, cracked skin, hyperkeratosis or senile dry skin.

BRIEF DESCRIPTION OF THE DRAWINGS It is a figure which shows the result of having measured the change with the passage of the date of the TEWL value of the skin site | part which apply | coated the test liquid containing AMP, and an uncoated skin site | part in Experimental example 3.
FIG. 2 is a diagram showing results obtained by measuring the change over time of the stratum corneum moisture content of the skin region to which the test solution containing AMP was applied and the uncoated skin region in Test Example 3. FIG.
3A is a photograph observing the skin surface form of the uncoated skin part 7 days after the start of the test in Test Example 3. FIG.
3B is a photograph observing the skin surface form of the skin region to which the test solution was applied 7 days after the start of the test in Test Example 3. FIG.

EMBODIMENT OF THE INVENTION Hereinafter, embodiment of this invention is described.

The preventive or therapeutic agent for abnormal skin moisture permeation function of the present invention is characterized by comprising at least one purine nucleic acid as an active ingredient. Hereinafter, "preventive agent or therapeutic agent for abnormal skin moisture permeation function of the present invention" may be referred to as "agent of the present invention".

"Purine nucleic acid" used as an active ingredient in the present invention is a generic term for various purine derivatives based on purine itself or purine nuclei, and salts thereof. As used herein, purine nucleic acid is not particularly limited as long as it is pharmaceutically or cosmetically acceptable. Examples of purine nucleic acids include adenine, guanine, deaminoated adenine (e.g. hipoxanthin) deaminoated guanine (e.g. xanthine), adenosine, guanosine, inosine, adenosine phosphate (e.g. adenosine 2'-monophosphate, Adenosine monophosphates such as adenosine 3'-monophosphate and adenosine 5'-monophosphate; adenosine diphosphates such as adenosine 5'-diphosphate; adenosine triphosphates such as adenosine 5'-triphosphate) and guanosine phosphate Guanosine monophosphate such as guanosine 3'-monophosphate and guanosine 5'-monophosphate; guanosine diphosphate such as guanosine 5'-diphosphate; guanosine triphosphate such as guanosine 5'-triphosphate) , Adenylosuccinic acid, xanthic acid, inosine acid, flavin adenine dinucleotide (FAD), nicotinamide adenine dinucleotide (NAD ), And the like. Among them, from the viewpoint of excellent TEWL control action, preferably adenosine phosphate, more preferably adenosine monophosphate, and particularly preferably adenosine 5'-monophosphate (AMP) is exemplified. These purine nucleic acids may be used alone, or may be used in combination of two or more thereof.

The salt of the purine nucleic acid is not particularly limited as long as it is pharmaceutically or cosmetically acceptable. Examples of the salts include alkali metal salts such as sodium salts and potassium salts; Alkaline earth metal salts such as magnesium salts, calcium salts and barium salts; Basic amino acid salts such as arginine salts and lysine salts; Ammonium salts such as ammonium salt and tricyclohexyl ammonium salt; Various alkanolamine salts, such as a monoethanolamine salt, a diethanolamine salt, a triethanolamine salt, a monoisopropanolamine salt, a diisopropanolamine salt, and a triisopropanolamine salt, etc. are mentioned. Among these salts, Alkali metal salts are preferred, and sodium salts are more preferred.

The agent of the present invention is used to improve the water permeation function of the stratum corneum and to enhance the water content control action of the skin. Accordingly, the agent of the present invention is provided as an external composition (external agent) such as cosmetics, external skin medicines or external skin quasi drugs used for the prevention or treatment of abnormal skin moisture permeation function, or for controlling the TEWL value.

In the external composition, the amount of purine nucleic acid can be appropriately set depending on the form of the preparation, the site of application, the expected effect, and the like. More specifically, the amount of purine nucleic acid in the external composition includes 0.1 to 20% by weight, preferably 0.5 to 10% by weight, more preferably 1 to 5% by weight, based on the total amount of the external composition. An external composition containing a purine nucleic acid in the above ratio can exert the regulating action of TEWL and the like.

In order to form an external composition using the agent of the present invention, purine nucleic acid may also be combined with various optional components commonly used in external preparations for skin, such as pharmaceutically or cosmetically acceptable carriers, additives, and the like. Such carriers and additives are known in the art and are appropriately set also for the blending amount thereof.

In the external composition, pH and osmotic pressure can be appropriately set within a range that does not adversely affect hypoallergenicity and good skin feel to the skin and mucous membranes.

The form of the external composition is not particularly limited as long as it is produced as a composition to be applied in external form to the skin, such as cosmetics, external skin medicines or external skin medications. For example, the agent of this invention mix | blends each said arbitrary component as needed, and also mix | blends the base material or carrier of the other solvent and the external agent used normally as needed, and is paste-like, mousse-like, gel-like, and liquid phase It can be manufactured as an external preparation of various desired forms, such as emulsion form, suspension form, cream form, ointment form, sheet form, aerosol form, spray form, and lining agent. Among these forms, liquid, emulsion, suspension and cream are preferred. These can be prepared according to conventional methods in the art.

The agent of the present invention is applied to the skin of a mammal (including humans) having abnormal skin moisture permeation function. Examples of abnormalities in skin moisture permeation function include skin diseases or skin conditions that exhibit excessive TEWL values or reduced TEWL values. Specific examples of the skin moisture permeation function or more include rough skin, itching, cracked skin, hyperkeratosis, senile dry skin and the like. Moreover, in this invention, the thing preferable for aging is a preferable example of the skin moisture permeation function abnormality. Regarding examples of TEWL values, reference may be made to Hachiro Tagami, "Kousho-kaishi (Journal of Cosmetic Science)" 27 (2003): 158.

In addition, agents of the invention are required to restore or maintain TEWL values in a healthy range, to prevent or treat abnormal TEWL in the skin, to restore or maintain skin water permeation function, or to control TEWL value ability. It can be applied to the target skin of mammals (including humans).

The agent of the present invention can prevent or treat abnormal skin moisture permeation function.

In addition, the agent of the present invention can improve the skin water permeation function to a normal state by controlling the TEWL value in a healthy range in mammals including humans. Therefore, the agent of the present invention can be used to provide a moisture moisturizing action and skin moisture permeation promoting action, or to adjust or restore the moisture content of the skin. More specifically, agents of the present invention can restore TEWL values to a healthy range by increasing TEWL for skin in a state where TEWL is reduced. In addition, agents of the present invention can restore TEWL values to a healthy range by reducing TEWL for skin exhibiting excess TEWL. For this reason, the agents of the present invention are effective for the prevention or treatment of skin conditions or skin diseases having abnormal TEWL values. For example, the agents of the present invention are effective in preventing or treating skin diseases and skin conditions (eg, dry skin, itching, cracked skin, hyperkeratosis, senile dry skin, etc.) with reduced TEWL values. In addition, the agents of the present invention are also effective, for example, in the prevention or treatment of skin diseases and skin conditions (eg, rough skin, etc.) exhibiting excessive TEWL values. The agent of the present invention can adjust the excess water content of the skin to an appropriate range, and also restore the low water content of the skin to an appropriate range. Because of this, the agents of the present invention are effective in restoring deteriorated water retention.

There is no particular limitation on the amount and number of times to apply the agent of the present invention. For example, an appropriate amount may be applied to the skin at a frequency of once or several times a day depending on the type and concentration of the active ingredient, the age, sex of the user, the severity of the skin condition, the application form, and the expected effect. In addition, about the application amount per one time of this invention, it is good to set it as the quantity which is 0.0001-1 mg, Preferably it is about 0.001 to about 1 mg per 1 cm <^{2> of} skin, for example.

In addition, the agent of the present invention can properly hydrate water from the epidermis while maintaining the proper amount of moisture in the skin by adjusting the TEWL value to a normal range, and thus can appropriately adjust the TEWL value ability. Thus, the agents of the present invention can be used as modulators of skin water permeation function or modulators of TEWL value ability.

In addition, the agents of the present invention can improve the TEWL value of the skin to a normal state. Therefore, the agent of the present invention can also be used as a prophylactic or therapeutic agent for abnormal TEWL (hard epidermal moisture evaporation amount).

<Examples>

Hereinafter, the present invention will be described in more detail with reference to test examples and examples. However, it should not be understood that the scope of the present invention is limited to these examples. In addition, in the following Examples etc., showing a compounding quantity with "%" means the weight% unless there is particular notice.

Test Example  1: adenosine Phosphate  Review of skin moisture permeation promoting action 1

This test example was conducted for the purpose of examining the skin moisture permeation promoting action of adenosine phosphate. In this test example, 12 healthy adults (10 males, 2 females; average age: 41.2 years old) were used as subjects. Specifically, an area of 9 × 8 cm provided on the left and right humeral side portions of the subject was used as the test site. A 20% ethanol aqueous solution (test solution) in which 3% of adenosine 5'-monophosphate sodium (AMP) was dissolved was applied to the left and right test sites in an appropriate amount, and the other test site was a 20% ethanol aqueous solution (base) containing no AMP. Equivalent amount was applied. Application | coating was performed twice a day (morning-afternoon) for 28 days, and the amount of TEWL and the horny layer moisture content before coating (before test) and after coating (after 28 days of coating) were measured.

The TEWL value (g / m ² / h) was measured using a DermaLab tester (manufactured by Cortex Technology, Inc.) according to the attached manual of the DermaLab tester (manufactured by Cortex Technology Inc.). The mean value of TEWL in each subject was calculated.

In addition, the moisture content of the stratum corneum was measured using the SKICON-200 tester (manufactured by IBS Co., Ltd.) and the electrical conductivity (μS) according to the attached manual of the SKICON-200 tester (manufactured by IBS Co., Ltd.). It was taken as an index of the moisture content of the stratum corneum.

Table 1 shows the measurement results of TEWL. As shown in Table 1, when the base was applied, there was substantially no change in the TEWL value before and after the test; On the other hand, after 28 days of application of the test solution, an increase in the TEWL value was observed, indicating that the skin moisture permeation function was enhanced.

In addition, the measurement result of the horny water content is shown in Table 2. As shown in Table 2, a significant increase in the amount of moisture in the stratum corneum was observed after 28 days of application of the test solution. It is generally believed that as TEWL rises, the moisture content of the stratum corneum decreases. However, it was clear from the results of this test that AMP has an effect of increasing TEWL moisture content while increasing TEWL.

From the above results, it was shown that AMP has an action of improving skin moisture permeation function of the skin, unlike a compound having a function of reducing TEWL.

Test Example  2: adenosine Phosphate  Review of skin moisture permeation promoting action 2

Next, the ethanol aqueous solution used in Test Example 1 was changed to the emulsion used as external cosmetics, and the same test as Test Example 1 was performed. Except for the change of the medium of the test solution and the change of the test site to the humerus side, the same conditions as in Test Example 1 were adopted for the subject, the test period, and the like. The emulsion used in this test used a general composition.

In addition, the corneal envelope (CE) of the stratum corneum was identified for the purpose of examining whether AMP application affects the barrier function of the skin. Specifically, in order to confirm the effect of AMP on the immature stratum corneum cell number, a stratum corneum was collected by applying a tape to the measurement site after 28 days of application of the test solution or base. The collected stratum corneum was stained using a fluorescently labeled anti-involuklin antibody, and the mature stratum corneum cells were then stained with a fluorescently labeled anti-mature cell antibody. Thereafter, each sample was examined under a fluorescence microscope to calculate the ratio of the immature stratum corneum cell number to the total stratum corneum cell number.

Table 3 shows the measurement results of TEWL. As shown in Table 3, when the base was applied, there was substantially no change in TEWL before and after the test; On the other hand, 28 days after application of the test solution, a clear increase in TEWL was observed, indicating that the skin moisture permeation function was enhanced.

In addition, the measurement result of the horny layer moisture content is shown in Table 4. As shown in Table 4, the increase in the moisture content of the stratum corneum was observed by the application of the base, but a more significant increase was observed when the test solution was used.

The increase in the amount of moisture in the stratum corneum by this base is considered to be a temporary stratum corneum moisturizing effect obtained by coating the so-called skin. On the other hand, it is thought that the increase of the stratum corneum moisture content and the moisture permeation function by the use of the test solution is the result of the improvement of the stratum corneum function and the water supply ability from the deeper skin layer to the outermost layer. For this reason, this effect is due to the improvement of skin function and ability itself, and it is thought that it will continue even after application | coating of test liquid is complete | finished.

In addition, the results of measuring the ratio of the immature stratum corneum cell number to the total stratum corneum cell number are shown in Table 5. In general, when many immature stratum corneum cells are seen in the stratum corneum, it is considered that the rough skin and the stratum corneum barrier function decrease. As shown in Table 5, even when the test solution containing AMP was applied, the rate of appearance of immature stratum corneum cell numbers did not increase. That is, it was confirmed that the skin barrier function was not lowered by the application of the test solution containing AMP.

From the results of this test, it was confirmed that the increase in the moisture content of the stratum corneum also appeared in the application of the AMP-free base, but the increase action of TEWL appeared only by the application of AMP. Accordingly, AMP has been shown to enhance the water permeation function of the original skin. In addition, it does not change the skin barrier function which decreases with the increase of the conventional TEWL at this time; AMP has been shown to be safe to use.

Test Example  3: Adenosine phosphate inhibits skin moisture permeation Review

Next, the action of adenosine phosphate on skin with excessively high skin moisture permeation function was examined. The test was conducted on 9 healthy adults (9 males; mean age: 43.1 years) as subjects. More specifically, a test site of 7 x 4.5 cm was set on the left and right outer abdominal sides of each subject. An aqueous solution of 0.25 w / v% sodium dodecyl sulfate (SDS aqueous solution, manufactured by Wako Junyaku Kogyo Co., Ltd.) was applied on both left and right test sites for 24 hours. After treatment with SDS aqueous solution, the application site was washed to obtain a rough skin model. An emulsion containing 3% of adenosine 5'-monophosphate sodium was used as a test solution. Adenosine 5'-monophosphate sodium emulsion was apply | coated appropriately on one side, and the other side was made non-coating. Application | coating was started after completion | finish of SDS aqueous solution process (day 0), and was performed twice a day for 7 days. Before treatment with SDS aqueous solution and after completion of treatment; After 1, 3 and 7 days of application of the test solution, the TEWL and the horny layer moisture content were measured in the same manner as in Test Example 1. In addition, the skin surface morphology 7 days after application of the test solution was observed. Morphological observation of the skin surface was performed using the microscope (Scalar Corporation).

The measurement result of TEWL is shown in FIG. As shown in FIG. 1, an apparent increase in TEWL value was observed by treatment with an aqueous SDS solution, and clear rough skin was also confirmed; Thereafter, at the site where the test solution was applied, more rapid reduction of TEWL was observed after 3 days and 7 days of application compared to the uncoated site.

In addition, the moisture content of the stratum corneum is shown in FIG. As shown in Fig. 2, the SDS aqueous solution treatment showed a clear decrease in the amount of stratum corneum moisture; Thereafter, the stratum corneum moisture content did not increase until after 7 days in the uncoated area, but a significant increase in the stratum corneum moisture content was observed in the site where the test solution was applied.

In addition, the results of observing the skin surface form is shown in Figures 3a and 3b. In the non-coated area (Fig. 3a), the pattern of the skin surface consisting of the skin groove, the skin tomb and the filament was lost, and peeling of the stratum corneum was also observed. On the other hand, in the site | part to which the test liquid containing AMP was apply | coated (FIG. 3B), a pattern was seen on the skin surface, and peeling of the stratum corneum was also not seen. In this respect, it was confirmed that a test solution containing AMP showed an effective improvement effect on rough skin due to excessive TEWL hyperactivity.

Claims (14)

Purine nucleic acids for preventing or treating skin water permeation dysfunction. The purine nucleic acid according to claim 1, which is selected from the group consisting of adenosine phosphate and salts thereof. The purine nucleic acid according to claim 1, which is selected from the group consisting of adenosine monophosphate and salts thereof. The purine nucleic acid according to claim 1, which is used in an amount of 0.1 to 20% by weight in the external composition. The purine nucleic acid according to claim 1, which is used for preventing or treating a skin condition or a skin disease having abnormal transepidermal water loss (TEWL) value. The purine nucleic acid according to claim 1, wherein the skin water permeation dysfunction is due to aging. The purine nucleic acid according to claim 1, wherein the skin moisture permeability abnormality is rough skin, itching, cracked skin, hyperkeratosis or senile dry skin disease. The purine nucleic acid according to claim 1, which is used as a component of a cosmetic, an external skin medicine or an external skin quasi drug. The purine nucleic acid according to claim 1, which is used for non-treatment. Purine nucleic acid for preventing or treating aberrant TEWL in skin. 11. The purine nucleic acid according to claim 10, wherein said abnormal TEWL is due to aging. Use of at least one purine nucleic acid for preparing an external composition for improving skin moisture permeation function. Purine nucleic acid for improving skin moisture permeation function. A method of improving skin moisture permeation function comprising administering at least one purine nucleic acid to a subject in need thereof to restore or maintain skin moisture permeation function.

Images